PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26224876-8 2015 Knock-in mice expressing an uncleavable p120 RasGAP mutant showed exaggerated NF-kappaB activation when their epidermis was treated with anthralin, a drug used for the treatment of psoriasis. Anthralin 137-146 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 78-87 8666828-0 1996 Anti-psoriatic drug anthralin activates transcription factor NF-kappa B in murine keratinocytes. Anthralin 20-29 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 61-71 8666828-4 1996 In this study, we show that at little as 10 microM anthralin can activate a prototypic form of transcription factor NF-(kappa)B, a central transcriptional regulator of inflammatory and immune responses. Anthralin 51-60 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 116-127 8666828-5 1996 Two different lines of evidence show that ROIs, in particular H2O2, are second messengers for the anthralin-induced NF-(kappa)B activation. Anthralin 98-107 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 116-127 8666828-8 1996 Our data suggest that ROI-induced NF-(kappa)B plays a role in the anti-psoriatic activity of the drug anthralin. Anthralin 102-111 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 34-45